Top Suppliers:I want be here
Related CAS#:
283609-79-0 162559-45-7
99764-63-3 142606-55-1
943235-75-4 425632-67-3
1926163-42-9 143648-02-6
73237-75-9 884009-99-8
1158522-08-7 940364-43-2
134104-43-1 131615-57-1
1550664-91-9 6906-52-1
930439-75-1 1018584-77-4
1375289-11-4 849349-65-1

283609-79-0

283609-79-0 structure
283609-79-0 structure
  • Name: H-Leu-Ser-Lys-Leu-NH2 trifluoroacetate salt
  • Chemical Name: LSKL-NH2
  • CAS Number: 283609-79-0
  • Molecular Formula: C21H42N6O5
  • Molecular Weight: 458.595
  • Catalog: Peptides
  • Create Date: 2018-06-12 17:26:09
  • Modify Date: 2024-01-11 02:06:36
  • LSKL, Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide, inhibits thrombospondin (TSP-1) activation of TGF-β and prevents the progression of hepatic damage and fibrosis.
Name LSKL-NH2
Synonyms L-Leucinamide, L-leucyl-L-seryl-L-lysyl-
L-Leucyl-L-seryl-L-lysyl-L-leucinamide
H-Leu-Ser-Lys-Leu-NH2
LSKL, Inhibitor of Thrombospondin (TSP-1)
Description LSKL, Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide, inhibits thrombospondin (TSP-1) activation of TGF-β and prevents the progression of hepatic damage and fibrosis.
Related Catalog
In Vitro LSKL peptide is able to reduce liver fibrosis by inhibiting TGF-β activation[2].
In Vivo LSKL (1 mg/kg, i.p.) can easily traverse the blood brain barrier. LSKL peptide also alleviates hydrocephalus and improves long-term cognitive function following SAH. Moreover, LSKL peptide inhibits subarachnoid fibrosis after SAH. LSKL treatment significantly decreases the activation of TGF-β1 in the CSF in comparison with that in the SAH+PBS group[1]. LSKL peptide (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL peptide successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL peptide accelerates hepatocyte proliferation after hepatectomy[3].
Animal Admin Wild-type 8–12-week-old male mice (C57BL/6) are used for all experiments. LSKL TSP-1 inhibitory peptide is diluted to 5 mg/mL with normal saline. In the LSKL peptide group, LSKL peptide (30 mg/kg bodyweight in 6 mL/kg) is administered intraperitoneally before abdominal wall closure and at 6 h after the 70 per cent hepatectomy. In the normal saline group, saline (6 mL/kg) is given intraperitoneally at the same time points. In the sham-operated group, laparotomy is performed and the incision is sutured after normal saline (6 mL/kg) have been administered intraperitoneally.
References

[1]. Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31.

[2]. Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61.

[3]. Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg. 2015 Jun;102(7):813-25.
Density 1.1±0.1 g/cm3
Boiling Point 817.8±65.0 °C at 760 mmHg
Molecular Formula C21H42N6O5
Molecular Weight 458.595
Flash Point 448.4±34.3 °C
Exact Mass 458.321655
LogP -0.49
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.521
Storage condition -20°C

Chemsrc provides CAS#:283609-79-0 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 283609-79-0 | Chemsrc address: https://m.chemsrc.com/en/baike/1467354.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved